If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of PDMR Dealing

13 Aug 2020 07:00

RNS Number : 9821V
Mereo BioPharma Group plc
13 August 2020
 

Mereo BioPharma Group plc

 

Notification of PDMR Dealing

 

London and Redwood City, Calif., August 13, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on August 12, 2020 John Lewicki, Chief Scientific Officer of Mereo, was granted options over 100,000 American Depositary Shares (ADSs) under the Mereo BioPharma Group plc 2019 equity incentive plan for no consideration. The exercise price for these options is USD 2.77 per ADS.

 

Option grants were also made to other Company personnel over a further 100,000 ADSs at the same exercise price.

 

This announcement and the notification below is made in accordance with the EU Market Abuse Regulation. The PDMR disclosure form required under the EU Market Abuse Regulation follows.

 

1

Details of the person discharging managerial responsibilities

a)

Name

John Lewicki

2

Reason for the notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$2.77 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

No consideration

100,000

 

 

d)

Aggregated information: volume, Price

e)

Date of the transaction

12-08-2020

f)

Place of the transaction

OUTSIDE OF A TRADING VENUE

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGZGMRGZDGGZZ
Date   Source Headline
3rd Nov 20052:53 pmRNSNotice of Interim Results
31st Oct 200510:54 amRNSBoard Changes
19th Oct 20057:00 amRNSAgreement extension
9th Sep 20057:00 amRNSDirector/PDMR Shareholding
6th Sep 200511:55 amRNSResult of AGM
2nd Sep 20059:39 amRNSHolding(s) in Company
19th Aug 200510:40 amRNSAcquisition
3rd Aug 20057:02 amRNSAcquisition
2nd Aug 20059:52 amRNSUpdate
20th Jul 20057:01 amRNSCollection in Flagship Stores
22nd Jun 20057:00 amRNSHolding(s) in Company
8th Jun 20057:00 amRNSFinal Results
12th May 200511:48 amRNSBlocklisting application
11th May 20057:00 amRNSLaunch in Japan
10th May 20057:00 amRNSNotice of Results
15th Apr 200511:59 amRNSStatement re. Press Comment
7th Apr 20057:00 amRNSre: Contracts
23rd Mar 200511:52 amRNSDirector Shareholding
23rd Mar 20057:00 amRNSMarchpole Update
21st Mar 20051:45 pmRNSBoateng Proceedings
24th Feb 20057:04 amRNSDirector Shareholding
24th Feb 20057:00 amRNSAgreement re Ungaro
22nd Feb 20057:00 amRNSDirector Shareholding
7th Feb 20051:52 pmRNSHolding(s) in Company
7th Feb 20057:00 amRNSHolding(s) in Company
1st Feb 20055:18 pmRNSDirector Shareholding
28th Jan 20052:21 pmRNSDirectorate Change
10th Jan 20057:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.